ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: Senate Cancer Coalition Hearing On Tamoxifin Planned for May 11; Bresnick Leads AACR

May 6, 1994

Freement Lists Steps For Dealing With Disadvantaged

September 7, 1990

NEJM Paper: Ownership of IMRT Centers Prompts Urologists to Refer Patients to Radiation Therapy

October 25, 2013

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

December 25, 2009

NCI Implementing Changes In Organ Site Program, Directing Grant applications To NIH Study Sections

October 15, 1982

Geography Still An Issue For Centers: Durant Asks Is It “Holy Water” or Money

April 26, 1985